JO3430B1 - مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها - Google Patents

مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها

Info

Publication number
JO3430B1
JO3430B1 JOP/2016/0126A JOP20160126A JO3430B1 JO 3430 B1 JO3430 B1 JO 3430B1 JO P20160126 A JOP20160126 A JO P20160126A JO 3430 B1 JO3430 B1 JO 3430B1
Authority
JO
Jordan
Prior art keywords
sub
preparation
pharmaceutical compositions
compositions containing
aminoacid derivatives
Prior art date
Application number
JOP/2016/0126A
Other languages
English (en)
Inventor
James Edward Paul Davidson
Francoise Perron-Sierra
Agnes Proszenyak
Alain Bruno
Zoltan Szlavik
Attila Paczal
Andras Kotschy
Levente Ondi
Marton Csekei
Olivier Geneste
James Brooke Murray
Zoltan Szabo
I-Jen Chen
Balazs Balint
Szabolcs Sipos
Gabor Radics
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Application granted granted Critical
Publication of JO3430B1 publication Critical patent/JO3430B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات لها الصيغة (<span dir="LTR">I</span>)<span dir="LTR">:</span> حيث تكون <span dir="LTR">R<sub>1</sub></span>، <span dir="LTR">R<sub>2</sub></span>، <span dir="LTR">R<sub>5</sub></span>، <span dir="LTR">R<sub>6</sub></span>، <span dir="LTR">R<sub>7</sub></span>، <span dir="LTR">R<sub>12</sub></span>، <span dir="LTR">X</span>، <span dir="LTR">Y</span>، <span dir="LTR">A</span>، <span dir="LTR">E</span> و<span dir="LTR">n</span> مثلما تم تحديده في الوصف. الأدوية.
JOP/2016/0126A 2015-06-23 2016-06-22 مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها JO3430B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555747A FR3037956B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
JO3430B1 true JO3430B1 (ar) 2019-10-20

Family

ID=54260901

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0126A JO3430B1 (ar) 2015-06-23 2016-06-22 مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها

Country Status (42)

Country Link
US (1) US10457687B2 (ar)
EP (1) EP3313850B1 (ar)
JP (1) JP6741698B2 (ar)
KR (1) KR102620905B1 (ar)
CN (1) CN107709334B (ar)
AR (1) AR105101A1 (ar)
AU (1) AU2016282837B2 (ar)
CA (1) CA2990089C (ar)
CL (1) CL2017003163A1 (ar)
CO (1) CO2017012830A2 (ar)
CR (2) CR20170571A (ar)
CU (1) CU20170164A7 (ar)
CY (1) CY1120991T1 (ar)
DK (1) DK3313850T3 (ar)
EA (1) EA034587B1 (ar)
EC (1) ECSP17082546A (ar)
ES (1) ES2703997T3 (ar)
FR (1) FR3037956B1 (ar)
GE (1) GEP20207075B (ar)
HK (2) HK1250234A1 (ar)
HR (1) HRP20181806T1 (ar)
IL (1) IL256191B (ar)
JO (1) JO3430B1 (ar)
LT (1) LT3313850T (ar)
MA (1) MA42232B1 (ar)
MD (1) MD3313850T2 (ar)
MX (1) MX368845B (ar)
MY (1) MY189472A (ar)
PE (1) PE20190111A1 (ar)
PH (1) PH12017502266A1 (ar)
PL (1) PL3313850T3 (ar)
PT (1) PT3313850T (ar)
RS (1) RS57961B1 (ar)
RU (1) RU2747673C2 (ar)
SA (1) SA517390583B1 (ar)
SI (1) SI3313850T1 (ar)
SV (1) SV2017005588A (ar)
TN (1) TN2017000521A1 (ar)
TW (1) TWI631124B (ar)
UA (1) UA123267C2 (ar)
UY (1) UY36733A (ar)
WO (1) WO2016207226A1 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CN110381937A (zh) * 2017-01-06 2019-10-25 法国施维雅药厂 Mcl-1抑制剂和紫杉烷化合物的组合及其用途和药物组合物
EA202090082A1 (ru) 2017-06-22 2020-05-22 Ле Лаборатуар Сервье Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции
WO2019035899A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
BR112020003180A2 (pt) 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TW202038960A (zh) 2018-11-14 2020-11-01 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202100184A (zh) 2019-05-20 2021-01-01 瑞士商諾華公司 Mcl-1抑制劑抗體-藥物結合物及使用方法
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
AU2021385349A1 (en) 2020-11-24 2023-06-22 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
ES2616255T3 (es) * 2008-04-30 2017-06-12 National Health Research Institutes Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
AP3391A (en) * 2010-12-20 2015-08-31 Glenmark Pharmaceuticals Sa 2-Amino-4-arylthiazole compounds as TROA1 antagonists
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2922858A4 (en) * 2012-11-20 2016-06-15 Univ Mcgill THIENOPYRIMIDINE INHIBITORS OF FARNESYL AND / OR GÉRANYLGÉRANYL PYROPHOSPHATE SYNTHASE
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MA42232B1 (fr) 2018-11-30
BR112017027645A2 (pt) 2018-08-28
US10457687B2 (en) 2019-10-29
UA123267C2 (uk) 2021-03-10
GEP20207075B (en) 2020-03-10
EP3313850A1 (en) 2018-05-02
FR3037956B1 (fr) 2017-08-04
EP3313850B1 (en) 2018-10-03
TN2017000521A1 (en) 2019-04-12
HRP20181806T1 (hr) 2018-12-28
RU2018102372A (ru) 2019-07-23
CR20170571A (es) 2018-02-20
RU2747673C2 (ru) 2021-05-12
MX368845B (es) 2019-10-18
TW201712018A (zh) 2017-04-01
CR20170590A (es) 2018-02-26
RS57961B1 (sr) 2019-01-31
PH12017502266B1 (en) 2018-06-11
HK1252113A1 (zh) 2019-05-17
AU2016282837A1 (en) 2018-01-18
IL256191A (en) 2018-02-28
CY1120991T1 (el) 2019-12-11
SV2017005588A (es) 2018-06-01
MY189472A (en) 2022-02-16
JP6741698B2 (ja) 2020-08-19
US20190031675A1 (en) 2019-01-31
PH12017502266A1 (en) 2018-06-11
CL2017003163A1 (es) 2018-06-15
SA517390583B1 (ar) 2022-02-20
UY36733A (es) 2016-12-30
DK3313850T3 (en) 2019-01-28
MA42232A (fr) 2016-12-29
CO2017012830A2 (es) 2018-03-28
MD3313850T2 (ro) 2019-02-28
ECSP17082546A (es) 2018-02-28
HK1250234A1 (zh) 2018-12-07
CN107709334B (zh) 2021-04-13
IL256191B (en) 2020-03-31
PE20190111A1 (es) 2019-01-15
WO2016207226A1 (en) 2016-12-29
LT3313850T (lt) 2018-11-26
MX2017016996A (es) 2018-08-23
PL3313850T3 (pl) 2019-04-30
TWI631124B (zh) 2018-08-01
CN107709334A (zh) 2018-02-16
FR3037956A1 (ar) 2016-12-30
AU2016282837B2 (en) 2020-05-28
CA2990089C (en) 2020-11-03
HK1252113B (zh) 2020-01-10
JP2018522856A (ja) 2018-08-16
EA201890123A1 (ru) 2018-05-31
CA2990089A1 (en) 2016-12-29
KR20180015261A (ko) 2018-02-12
EA034587B1 (ru) 2020-02-25
ES2703997T3 (es) 2019-03-13
SI3313850T1 (sl) 2019-01-31
CU20170164A7 (es) 2018-05-08
RU2018102372A3 (ar) 2019-11-06
KR102620905B1 (ko) 2024-01-04
AR105101A1 (es) 2017-09-06
PT3313850T (pt) 2018-11-29

Similar Documents

Publication Publication Date Title
JO3430B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
JO3583B1 (ar) مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201891544A1 (ru) Ингибиторы простатического специфического мембранного антигена (псма) на основе мочевины для визуализации и лечения
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
JO3648B1 (ar) عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201890895A1 (ru) Мультивалентные и моновалентные мультиспецифические комплексы и их применение
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2019015744A (es) Composiciones farmaceuticas.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
EA201591451A1 (ru) Модуляторы flap
TW201613864A (en) Novel compounds
JO3402B1 (ar) ملح جديد للأبيكسينوستات ,شكل بلوري مرافق , طريقة تحضيرها والتركيبات الصيدلانية التي تحتوي عليها
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
JO3457B1 (ar) مركبات الايزو اندولين أو الايزو كوينولين الجديدة وعملية لتحضيرها والتركيبات الدوائية التي تحتوي عليها
MX2018001517A (es) Derivados sustituidos de guanidina.